Treatment of brain metastases of lung cancer in the era of precision medicine

Front Biosci (Elite Ed). 2016 Jan 1;8(1):219-32. doi: 10.2741/E763.


Common and deadly complications of non-small cell lung cancer (NSCLC) are brain metastases (BM). BM portends a poorer prognosis with limited effective treatment options and current management strategies present several challenges from iatrogenic complications of supportive medications, optimal delivery of drug across the blood-brain barrier, and preservation of neurocognitive function. Long term side effects and survivorship issues have become more evident in the era of targeted therapy where a systemic disease is much better controlled. Targeted therapies and immunotherapy are beginning to provide improvements in responses and survival rates. With further advancements and experience, our knowledge in this era of precision medicine will likely lead to strides in improving the quality of life and overall survival of patients with BM from NSCLC. In this review, we present the most recent updates in treatment of BM in NSCLC in regards to targeted and immunotherapy.

MeSH terms

  • Brain Neoplasms / blood supply
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Humans
  • Immunotherapy
  • Lung Neoplasms / pathology*
  • Molecular Targeted Therapy
  • Neovascularization, Pathologic